Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. Company
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development and commercialization of medicines to treat cancers. Its platform also provides therapies to cancer patients with additional treatment options. The Company's cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. The products derived from cabozantinib are CABOMETYX tablets for renal cell carcinoma (RCC) and COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). Its other two product candidates are COTELLIC (cobimetinib), is an inhibitor of MEK with multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO (esaxerenone), is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) for the treatment of hypertension. Its phase I b clinical trial programs include XL092, STELLAR-001 and STELLAR-002.

Number of employees : 773 people.
Sales per Business
2020
Product741.5575.1%
License167.3016.9%
Collaboration Service78.698%
USD in Million
Sales per region
20192020Delta
United States770.2479.6%752.8976.2% -2.25%
Europe152.7715.8%151.6315.4% -0.75%
Japan44.764.6%83.028.4% +85.47%
USD in Million
Managers
Name Title Age Since
Michael Morrissey President-Research & Development 60 2007
Christopher Senner Chief Financial Officer & Executive Vice President 53 2015
Peter Lamb Chief Scientific Officer & EVP-Scientific Strategy 60 2016
Vicki Goodman Chief Medical Officer - 2022
Dana Aftab Executive Vice President-Business Operations - 2016
Jack L. Wyszomierski Independent Director 65 2004
George A. Poste, Dr. Independent Director 76 2004
Charles M. Cohen, Dr. Independent Director 70 1995
Stelios Papadopoulos Director 72 1994
Lance Willsey, Dr. Independent Director 59 1997
Members of the board
Name Title Age Since
Stelios Papadopoulos Director 72 1994
Jack L. Wyszomierski Independent Director 65 2004
George A. Poste, Dr. Independent Director 76 2004
Charles M. Cohen, Dr. Independent Director 70 1995
Lance Willsey, Dr. Independent Director 59 1997
Vincent T. Marchesi, Dr. Independent Director 85 2001
Carl B. Feldbaum Independent Director 77 2007
Alan M. Garber, Dr. Independent Director 65 2005
Michael Morrissey President-Research & Development 60 2007
Julie Anne Smith Independent Director 50 2016
Shareholders
NameEquities%
The Vanguard Group, Inc. 29,614,558 9.36%
Capital Research & Management Co. (Global Investors) 22,565,030 7.13%
Fidelity Management & Research Co. LLC 18,285,673 5.78%
Renaissance Technologies LLC 17,547,501 5.55%
T. Rowe Price Associates, Inc. (Investment Management) 17,237,135 5.45%
SSgA Funds Management, Inc. 10,606,520 3.35%
Meditor Capital Management Ltd. 10,030,700 3.17%
Matrix Capital Management Co. LP 10,000,000 3.16%
Farallon Capital Management LLC 9,659,712 3.05%
JPMorgan Investment Management, Inc. 9,341,225 2.95%
Company contact information
Exelixis, Inc.
1851 Harbor Bay
Alameda, CA 94502

Phone : +1.650.837.7000
Fax : +1.650.837.8300
Web : http://www.exelixis.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Exelixis, Inc.
Sector Bio Therapeutic Drugs